Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...

2015年3月25日 · Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities.

The potential to transform the lives of patients is what drives us at Biogen. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.

Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most. Explore our business areas to discover where you can make an impact on our team.

Biogen. Science & Innovation. Pipeline. Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health. This is made possible by people who ...

As pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of significantly altering the course of MS and preventing disease development and …

Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS.

2 天之前 · For product information for other countries, please visit your country's Biogen affiliate website. Last Updated: April 8, 2025

2025年3月25日 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.